Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

Flowerfields

Financiado

Cerrado

Early stage tumour markers based on the Flower proteins

It is unquestioned that early detection of cancer is a major factor contributing to therapy outcome. Unfortunately, only few tumour markers have been identified for early stage cancers to date, and the reliable detection of tumour... ver más

31/01/2014

UNIVERSITAET BERN

155K€

Presupuesto del proyecto: 155K€

Líder del proyecto

UNIVERSITAET BERN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-01-31 No tenemos la información de la convocatoria

0% 89% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UNIVERSITAET BERN

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CANOMICS Multicentre discovery of breast cancer biomarkers 86K€ Cerrado

RTC-2017-6271-1 Desarrollo tecnológico para cuantificar en suero un nuevo ma... 405K€ Cerrado

Signaling 3D Three Dimensional Single Cell Analysis of the Cancer Stem Ce... 2M€ Cerrado

CTQ2015-64402-C2-2-R NUEVAS PLATAFORMAS DE MULTIPLEXADO ELECTROANALITICAS PARA LA... 105K€ Cerrado

CANDLE Cancer Diagnosis by Multiplex Protein Epitope Profiling 71K€ Cerrado

EpiCblood Towards early cancer detection and tumor classification usin... 1M€ Cerrado

Líder del proyecto

UNIVERSITAET BERN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 155K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto It is unquestioned that early detection of cancer is a major factor contributing to therapy outcome. Unfortunately, only few tumour markers have been identified for early stage cancers to date, and the reliable detection of tumours before the manifestation of morphological changes still remains an unresolved problem in routine clinical diagnosis. A recent study came to the conclusion that shedding rates of currently available cancer biomarkers are a factor of 10-4 below the necessary sensitivity to reliably detect cancers during their first decade. In other studies, the reliability of currently existing biomarkers such as the PSA-marker for prostate cancer is questioned. The development of alternative early-stage tumour markers, in particular also for epithelial cancers, is therefore urgently necessary. FLOWERFIELDS is aimed to provide means and methods to detect such cancer cells before an aggressive tumour is formed. To that end, we plan to exploit the extracellular molecular code called The Flower Code (Fwe) that is expressed in very early stage cancer or precancerous cells. Fwe may be integrated into routine immuno- or PCR-assays for the detection of a variety of epithelial cancers. Applications may include early-stage diagnosis but also the evaluation of therapy outcome. The current project has two aims: (i) to develop improved ligands for ELISA diagnostic tests for Flower gene expression, (ii) to validate the concept clinically on human samples in both immuno- and PCR-based assays. The clinical validation of a biomarker candidate is a key success factor for being able to feed it into development stage of a commercial partner.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores